ArticleTherapeutic advances in medical oncology2026
Integrating intracranial hypofractionated radiotherapy with immunotherapy for melanoma brain metastases: therapeutic impact and immune modulation.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Combined radiotherapy and immunotherapy can enhance antitumor efficacy, but its effects on melanoma brain metastases (MBM) remain unclear. Objectives: To evaluate the intracranial efficacy, safety, and exploratory immune biomarkers of zimberelimab combined with intracranial hypofractionated radiotherapy in patients with MBM. Methods: Eligible patients were aged 18-75, had an Eastern Cooperative Oncology Group performance status of 0-2 and measurable brain metastases. Patients received 30-50 Gy/5-10 fractions intracranial hypofractionated radiotherapy and two cycles zimberelimab (240 mg every 3 weeks). The primary endpoint was the intracranial objective response rate (ORR). Secondary endpoints included the disease control rate, overall survival, progression-free survival (PFS), quality of life, safety and potential biomarkers. In addition, serum cytokines were profiled and linked to proteomics-based exploratory prognostic model constructed using the UK Biobank dataset. Results: Between November 2022 and February 2025, 10 patients, with median age 60.5 years, completed the treatment, and their data were analyzed. The median intracranial metastatic lesion size was 2.4 cm (range 1.0-5.9 cm). The intracranial ORR was 70%, and intracranial disease control rate was 90%. The median overall survival and intracranial PFS were both 12 months, while the overall PFS was 10.5 months. The patients' quality of life improved, without grade ⩾3 treatment-related adverse events. Furthermore, post-treatment increases in selected immune-related biomarkers, such as CXCL9, were descriptively associated with treatment response, and baseline levels showed exploratory associations with survival outcomes. Conclusion: HFRT plus zimberelimab demonstrated promising intracranial activity, quality of life improvement, and acceptable early safety in patients with MBM and may potentially induce an abscopal antitumor effect. Exploratory immune analyses suggest that baseline immune readiness and therapy-induced immune activation may be associated with treatment benefit. Design: This was a prospective, single-arm, open-label phase II study. Trial registration: ChiCTR, ChiCTR2200057001. Registered 25 February 2022 (https://www.chictr.org.cn/showproj.html?proj=153144).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.